The Combination of Adenoviral HSV TK Gene Therapy and Radiation is Effective in Athymic Mouse Glioblastoma Xenografts Without Increasing Toxic Side Effects

Overview

Journal J Neurooncol

Publisher Springer

Date 2004 Apr 10

PMID 15072465

Citations 15

Authors

Ulf Nestler

Hiroaki Wakimoto

Fernando Siller-Lopez

Laura K Aguilar

Arnab Chakravarti

Alona Muzikansky

Anat Stemmer-Rachamimov

E Antonio Chiocca

Estuardo Aguilar-Cordova

Fred H Hochberg

Affiliations

Soon will be listed here.

Abstract

Object: In mouse models of prostate and breast cancer therapeutic effects are enhanced when adenoviral HSV TK gene therapy is combined with ionizing radiation. In the present study, we adopted this approach for the treatment of human glioblastoma xenografts in an athymic mouse model and assessed treatment results as well as toxic side effects.

Methods: About 72 nude mice received intracerebral inoculations of 2 x 10(5) U87deltaEGFR cells. On day 7 after tumor implantation the study population was randomized into six treatment arms: (1) intratumoral buffer inoculation on day 7, (2) intratumoral adenoviral vector injection (2 x 10(9) vp) on day 7, (3) single dose radiation (2.1 Gy) on day 9, (4) adenoviral injection + radiation, (5) adenoviral injection + ganciclovir (GCV) (20 microg/g twice daily from day 8 to 17), (6) adenoviral injection + GCV + radiation. On day 21 half of the animals were sacrificed for histological evaluation of the brain tumors, the other half was assessed for survival.

Results: This study showed significantly prolonged median survival time of 5 days for the GCV treated groups. The addition of radiation decreased the frequency of neurological symptoms and delayed the onset of deficits without altering the expression of thymidine kinase in the tumor cells.

Conclusions: We conclude that adenoviral HSV TK gene therapy in combination with adjuvant radiotherapy does not generate increased toxic side effects in glioblastoma treatment. The prolonged survival time of animals receiving gene therapy and the reduced occurrence of neurological symptoms in irradiated mice constitute promising features of the combined treatment.

Citing Articles

Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?.

Chen E, Ling A, Reardon D, Chiocca E Neuro Oncol. 2023; 26(2):211-225.

PMID: 37995317 PMC: 10836778. DOI: 10.1093/neuonc/noad211.

Advances in immunotherapy for glioblastoma multiforme.

Mahmoud A, Ajina R, Aref S, Darwish M, Alsayb M, Taher M Front Immunol. 2022; 13:944452.

PMID: 36311781 PMC: 9597698. DOI: 10.3389/fimmu.2022.944452.

Advances in local therapy for glioblastoma - taking the fight to the tumour.

van Solinge T, Nieland L, Chiocca E, Broekman M Nat Rev Neurol. 2022; 18(4):221-236.

PMID: 35277681 PMC: 10359969. DOI: 10.1038/s41582-022-00621-0.

A Herpes Simplex Virus Thymidine Kinase-Induced Mouse Model of Hepatocellular Carcinoma Associated with Up-Regulated Immune-Inflammatory-Related Signals.

Gong Z, Ma Q, Wang X, Cai Q, Gong X, Genchev G Genes (Basel). 2018; 9(8).

PMID: 30060537 PMC: 6115908. DOI: 10.3390/genes9080380.

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.

Wheeler L, Manzanera A, Bell S, Cavaliere R, McGregor J, Grecula J Neuro Oncol. 2016; 18(8):1137-45.

PMID: 26843484 PMC: 4933478. DOI: 10.1093/neuonc/now002.

References

Goodman J, Trask T, Chen S, Woo S, Grossman R, Carey K . Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. Hum Gene Ther. 1996; 7(10):1241-50. DOI: 10.1089/hum.1996.7.10-1241. View

Aghi M, Hochberg F, Breakefield X . Prodrug activation enzymes in cancer gene therapy. J Gene Med. 2000; 2(3):148-64. DOI: 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q. View

Freyer J . Role of necrosis in regulating the growth saturation of multicellular spheroids. Cancer Res. 1988; 48(9):2432-9. View

Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Suit H . Quantitative comparison between the transplantability of human and murine tumors into the brain of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res. 1993; 53(20):5018-21. View

Nestler U, Heinkelein M, Lucke M, Meixensberger J, Scheurlen W, Kretschmer A . Foamy virus vectors for suicide gene therapy. Gene Ther. 1998; 4(11):1270-7. DOI: 10.1038/sj.gt.3300561. View

Valerie K, Hawkins W, FARNSWORTH J, Schmidt-Ullrich R, Lin P, Amir C . Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther. 2001; 8(1):3-8. DOI: 10.1038/sj.cgt.7700265. View

Rojas-Martinez A, Wyde P, MONTGOMERY C, Chen S, Woo S, Aguilar-Cordova E . Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat. Cancer Gene Ther. 1999; 5(6):365-70. View

Packer R, Raffel C, Villablanca J, Tonn J, Burdach S, Burger K . Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg. 2000; 92(2):249-54. DOI: 10.3171/jns.2000.92.2.0249. View

Raza S, Lang F, Aggarwal B, Fuller G, Wildrick D, Sawaya R . Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery. 2002; 51(1):2-12; discussion 12-3. DOI: 10.1097/00006123-200207000-00002. View

10.

Alvarez R, Gomez-Navarro J, Wang M, Barnes M, Strong T, Arani R . Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther. 2000; 2(5):524-30. DOI: 10.1006/mthe.2000.0194. View

11.

Vlachaki M, Chhikara M, Aguilar L, Zhu X, Chiu K, Woo S . Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys. 2001; 51(4):1008-17. DOI: 10.1016/s0360-3016(01)01698-4. View

12.

Shine H, Wyde P, Aguilar-Cordova E, Chen S, Woo S, Grossman R . Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). Gene Ther. 1997; 4(4):275-9. DOI: 10.1038/sj.gt.3300397. View

13.

Leskov K, Criswell T, Antonio S, Li J, Yang C, Kinsella T . When X-ray-inducible proteins meet DNA double strand break repair. Semin Radiat Oncol. 2001; 11(4):352-72. DOI: 10.1053/srao.2001.26912. View

14.

Chen S, Shine H, Goodman J, Grossman R, Woo S . Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A. 1994; 91(8):3054-7. PMC: 43513. DOI: 10.1073/pnas.91.8.3054. View

15.

Zolzer F, Streffer C . Quiescence in S-phase and G1 arrest induced by irradiation and/or hyperthermia in six human tumour cell lines of different p53 status. Int J Radiat Biol. 2000; 76(5):717-25. DOI: 10.1080/095530000138394. View

16.

Sutherland R . Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988; 240(4849):177-84. DOI: 10.1126/science.2451290. View

17.

Kaaijk P, Troost D, Sminia P, Hulshof M, van der Kracht A, Leenstra S . Hypofractionated radiation induces a decrease in cell proliferation but no histological damage to organotypic multicellular spheroids of human glioblastomas. Eur J Cancer. 1997; 33(4):645-51. DOI: 10.1016/s0959-8049(96)00503-5. View

18.

Little J . Delayed initiation of DNA synthesis in irradiated human diploid cells. Nature. 1968; 218(5146):1064-5. DOI: 10.1038/2181064a0. View

19.

Ram Z, Walbridge S, Shawker T, Culver K, Blaese R, Oldfield E . The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg. 1994; 81(2):256-60. DOI: 10.3171/jns.1994.81.2.0256. View

20.

Chhikara M, Huang H, Vlachaki M, Zhu X, Teh B, Chiu K . Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther. 2001; 3(4):536-42. DOI: 10.1006/mthe.2001.0298. View